Overview

Chemotherapy Followed by Allogeneic Stem Cell Transplantation for Hematologic Malignancies

Status:
Completed
Trial end date:
2020-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine disease-free survival, overall survival, time to progression, regimen-related toxicity and/or treatment-related mortality in patients with hematologic malignancies treated with non-myeloablative chemotherapy followed by allogeneic stem cell transplant.
Phase:
N/A
Details
Lead Sponsor:
Dartmouth-Hitchcock Medical Center
Treatments:
Cyclophosphamide
Cyclosporine
Cyclosporins
Fludarabine
Fludarabine phosphate
Methotrexate